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MAPK signaling cascades are evolutionally conserved. The bacterial effector, YopJ, uses the unique activity of Ser/Thr
acetylation to inhibit the activation of the MAPK kinase (MKK) and prevent activation by phosphorylation. YopJ is also able to
block yeast MAPK signaling pathways using this mechanism. Based on these observations, we performed a genetic screen to
isolate mutants in the yeast MKK, Pbs2, that suppress YopJ inhibition. One suppressor contains a mutation in a conserved
tyrosine residue and bypasses YopJ inhibition by increasing the basal activity of Pbs2. Mutations on the hydrophobic face of
the conserved G a-helix in the kinase domain prevent both binding and acetylation by YopJ. Corresponding mutants in human
MKKs showed that they are conserved not only structurally, but also functionally. These studies reveal a conserved binding site
found on the superfamily of MAPK kinases while providing insight into the molecular interactions required for YopJ inhibition.
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INTRODUCTION
The bacterial pathogen Yersinia pestis was the causal agent of three
pandemics referred to as the Plague of Justinian, Black Death and
the Third Pandemic [1]. Two other related bacterial pathogens,
Yersinia pseudotuberculosis and Yersinia enterocolitica are causal agents for
gastroenteritis [1]. All of the three Yersinia species harbor a 70 Kb
virulence plasmid that encodes a Type III Secretion System
(TTSS) and effector proteins [2]. The TTSS functions like a
syringe, whereby it injects or translocates effectors, also referred to
as Yops (Yersinia outer proteins), from the bacterial cell into the
infected host cell [2]. Yops are essentially bacterial equivalents of
viral oncogenes in that they mimic or capture a eukaryotic activity
to target and manipulate eukaryotic signaling machineries during
infection. However, unlike viral proteins that are made in the host,
effectors are made in bacteria and therefore must be kept in a
quiescent state until after they are translocated into the host. The
effectors are silenced in bacteria by a number of mechanisms
including association with a chaperone and/or lack of a eukaryotic
activator or substrate [3].
One of the Yersinia effectors, YopJ, is a 32 kD effector protein
that disrupts the innate immune response and promotes apoptosis
in infected cells by blocking the MAPK pathways and the NFkB
pathway [1,4]. YopJ disrupts these signaling systems by blocking
the activation of all MAP kinase kinases (MKKs) and IKKb (but
not IKKa)[4]. YopJ requires an intact catalytic triad consisting of
the concserved residues His, Cys and Glu/Asp for its inhibitory
activity [5]. Previous over-expression studies implicated various
mechanisms for YopJ’s inhibitory activity, but failed to identify a
specific substrate [5–8]. Recently it was discovered that YopJ is an
acetyltransferase that inhibits the activation of these kinases by
modifying serine and/or threonine residues in the activation loop
thereby preventing their modification by phosphorylation [9,10].
It is predicted that YopJ uses a two-substrate, ping-pong
mechanism similar to that used by a cysteine protease, whereby
the first substrate interacts with the enzyme, forming a high-energy
acyl-enzyme intermediate, that is attacked by the second substrate
resulting in a modified product [10,11]. However, in contrast to a
protease that uses a peptide and water for substrates, YopJ uses
acetyl-CoA and a hydroxyl from the R group on an amino acid.
The mechanism YopJ uses to inhibit the MAPK pathways is
evolutionarily conserved because YopJ was able to inhibit the
MAPK pathways in Saccharomyces cerevisiae, including the mating
and HOG pathways [12]. Herein, we established that YopJ blocks
the HOG pathway by blocking activation of the yeast MKK, Pbs2,
by acetylation. Based on these observations, we performed a
targeted suppressor screen in yeast using YopJ’s inhibitory effect
on HOG MAPK pathway to help gain further insight into the
molecular mechanism of YopJ inhibition of the MKKs and the
interactions between MKKs and YopJ.
A genetic screen was performed to isolate suppressor mutations
in Pbs2 that would allow growth on hyper-osmotic media in the
presence of YopJ. We identified a novel mutation in conserved
tyrosine that when mutated results in a constitutively active kinase.
Other suppressor mutations in Pbs2 revealed a conserved binding
site for YopJ on the MKKs. These studies not only provide
mechanistic insight into the inhibitory activity of the Yersinia
effector YopJ but also support predictions for mechanisms
involved in the activation of the kinases that are sensitive to
YopJ’s inhibition.
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YopJ binds, acetylates and inhibits activation of
Pbs2
We demonstrated that YopJ is able to block the HOG MAPK
signaling pathway downstream of the negative regulator Sln1
(Figure 1A) [12]. As shown in Figure 1B, the growth of yeast
expressing YopJ is arrested when grown on galactose/sorbitol
plates, while strains containing either the empty vector or
expressing the catalytically inactive YopJ-C172A mutant (YopJ-
C/A) are able to grow on galactose/sorbitol selective media. To
confirm that YopJ blocks the HOG pathway in a manner similar
to that observed for the mammalian MAPK pathways by preventing
activation of MKKs, we generated a yeast strain that contained an
activatedformofyeastMKKKSsk2(Ssk2DN)underthecontrolofa
galactose inducible promoter (Figure 1B) [13]. We observed that
growth of the Ssk2DN strains on galactose was arrested due to
constitutive activation of the HOG pathway in the absence of a
hyper-osmotic growth environment (Figure 1B) [13]. However, co-
expression of YopJ in this cell line rescued the growth arrest
phenotype, thereby supporting the hypothesis that YopJ inhibits the
HOG pathway downstream of the MKKK (Figure 1A, B).
To further confirm whether YopJ inhibits the signaling pathway
by preventing activation of the Pbs2 (yeast MKK) in the HOG
pathway, phospho-mimic mutants of Pbs2, in which either the
serine or threonine in the activation loop of the kinase were
replaced with aspartate (Pbs2(S514D) or Pbs2(T518D)), were
coexpressed with an empty vector, YopJ or YopJ-C/A mutant. We
observed that both mutants grow in the presence of 1M sorbitol
and YopJ (Figure 1B). These observations support the findings of
previous cell epistasis experiments, whereby YopJ was unable to
block the mammalian ERK MAPK signaling pathway down-
stream of the activated MKK1-EE [4].
We next assessed whether YopJ could bind to the yeast MKK
Pbs2, using yeast two-hybrid analysis. As previously observed for
mammalian MKK [4], both YopJ and YopJ-C172A were able to
interact with wild type Pbs2 (Figure 1C). Two hybrid analysis
with a panel of Pbs2 mutants, including inactive Pbs2
(Pbs2(S514A;T518A)), and activated Pbs2 (Pbs2(S514D;T518D)),
revealed that changes in amino acids that cause a change in the
charge of the activation loop and/or the activity of the enzyme do
not affect the binding of YopJ to Pbs2 (Figure 1C).
Recently, it was demonstrated that YopJ prevents the activation
of MKKs by acetylating the serine and threonine residues in the
MKK activation loop, thereby preventing their phosphorylation
by upstream kinases [9,10]. We confirmed that the Pbs2 kinase
domain (331–668 aa) is a substrate for YopJ acetylation
(Figure 1D). The substrate specificity of YopJ for the SXXXT
motif in the activation loop of Pbs2 was confirmed using site-
directed mutagenesis of this motif. A single mutation in Pbs2 of
either the Ser514 or Thr518 to an alanine results in a substrate
that can be acetylated by YopJ (data not shown). However, the
double mutation in Pbs2 (Ser514Ala;Thr518Ala) produced a
substrate that is no longer acetylated by YopJ, supporting the
proposal that these are the two residues that are modified and
preventing phosphorylation (Figure 1D).
Isolation of suppressor mutations in Pbs2
YopJ inhibits growth of yeast in the presence of sorbitol (Figure 1B,
2A) [12]. We screened a PCR random mutagenesis library of Pbs2
(,one mutation/kb DNA) for suppressor mutations in Pbs2 that
would allow cells to grow on media with 1M sorbitol when YopJ was
expressed. The screen was carried out in the pbs2D haploid strain to
ensure that the suppressor mutations inPbs2 contained the following
two properties: (1) the mutants are enzymatically active, and (2) the
mutants suppress growth inhibition induced by YopJ expression.
We recovered eighty strains containing suppressor mutations in
Pbs2 from the 9610
4 transformants screened. Pbs2 is a scaffolding
kinase with domains that bind both the upstream MKKK and the
downstream MAPK Hog1 [14]. We narrowed our focus to
mutations found exclusively in the kinase domain of Pbs2 and to
residues that are conserved in the mammalian and yeast MKKs.
After elimination of number of mutants, we finally focused on
three unique suppressor mutants (P1, P4, P5) that prevented YopJ
inhibition of the HOG MAPK signaling pathway as indicated by
growth in the presence of sorbitol (Figure 2A).
Suppressor mutations in Pbs2 map to evolutionarily
conserved residues
The three suppressor mutations in Pbs2 are due to changes in
amino acids that are evolutionarily conserved in all the MKK
family members (Figure 2C). The mutations map to three
locations on a canonical MKK structure: P1, on the center of
beta strand 4 in the conserved motif X-F-Y-G-A-X; P4 and P5, on
and at the end of the G helix, respectively (Figure 2D)[15]. These
findings are consistent with our previous observation that YopJ
interacts with and inhibits MKK family members by a common
mechanism [10,12].
We predicted that the suppressor mutations in Pbs2 could inhibit
YopJ by a variety of mechanisms. If the suppressor mutants had
increased basal activity, they would bypass YopJ inhibition in a
manner similar to that observed for Pbs2(S514D) and Pbs2(T518D)
(Figure 1B). Therefore, we tested whether any of the suppressor
mutations in Pbs2 contained increased basal activity or constitutive
activity by plating the yeast strains on glucose in the absence of
osmotic stimulus. Out of the three suppressor mutants, P1, grew
more slowly on glucose media when compared to the other yeast
strains grown on plates or in liquid media containing glucose as a
carbon source (Figure 2B and data not shown, respectively),
supporting the hypothesis that this mutant might bypass the growth
inhibition induced by YopJ with increased basal kinase activity.
From previous studies we have observed that YopJ inhibits only
the kinases to which it binds (all MKKs and IKKb) but not kinases
it does not bind (IKKa, Raf, p38, ERK1/2, Jnk) [4]. Therefore,
we predicted that one mechanism to suppress YopJ inhibition
would be to prevent binding of YopJ to its target kinase. Using the
yeast two-hybrid assay, we analyzed whether the suppressor
mutants could bind to YopJ and observed that one of these
mutants, P4, was unable to interact with YopJ (Figure 3A).
Because the remaining suppressor mutants (P1, P5) were able to
bind to YopJ, we propose that binding of YopJ to Pbs2 may be
necessary but not sufficient for YopJ’s inhibition. As expected,
analogous mutations made in mammalian MKK1, resulted a
similar profile of binding to YopJ as assessed by yeast two-hybrid
(Figure 3B), reinforcing the proposal that YopJ inhibits the MKKs
by a common mechanism [4,10].
Another possible mechanism for suppression of YopJ inhibition
would be that YopJ cannot acetylate the mutants. To test this
hypothesis, the kinase domain from each of the suppressor mutants
was purified from bacteria and tested as a substrate for YopJ in an in
vitro acetylation reaction. We observed that the kinase domains of
bothwildtypeand P1kinasedomains were efficiently acetylated, but
notthatofP5(Figure4).Aspredicted,theP4mutant,whichdoesnot
bind to YopJ, cannot be acetylated (Figure 4).
Finally, we tested whether the mutants could suppress the YopJ-
mediated inhibition of growth, when the mutants are co-expressed
with Pbs2. We observed that P1, but not P4 or P5, co-expressed
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Figure S2).
Overall, the isolated mutants show three distinct phenotypes: 1.
increased basal activity and suppression of YopJ in the presence of
endogenous Pbs2 (P1); 2. inability to bind and be acetylated by
YopJ, but unable to suppress YopJ in the presence of endogenous
Pbs2 (P4); and 3. inefficient acetylation by YopJ and unable to
suppress YopJ in the presence of endogenous Pbs2 (P5). Below, we
delineate the properties and mechanisms utilized by each
suppressor mutant to prevent YopJ inhibition of MAPK signaling.
Figure 1. YopJ binds, acetylates and inhibits activation of Pbs2. (A) Schematic representation of the canonical MAPK pathway aligned with the
yeast HOG MAP kinase pathway. (B) Yeast pbs2D strain is cotransformed with pRS416-GPD1-Pbs2 wild type, S514D or T518D mutants and pRS413-
Gal1 vector, YopJ or YopJ(C172A) mutant. pRS415-Gal1-Ssk2DN mutant is also transformed to the pRS416-GPD1-Pbs2 wild type strains (the third
panel). Strains are plated on media containing 2% glucose or 2% raffinose, 1% galactose with or without 1 M sorbitol and incubated at 30uC. (C) Yeast
two-hybrid assay of the interaction between YopJ or YopJ(C172A) mutant and Pbs2 wild type, Pbs2 dead mutant (AA) or Pbs2 constitutively active
mutant (DD). (D) Recombinant YopJ or YopJ(C172A) are incubated with or without purified Pbs2 kinase domain (Pbs2KD(WT)) or Pbs2 (S514A, T518A)
mutant (AA) kinase domain (Pbs2KD(AA)) in the presence or absence of
14C-labeled acetyl-CoA at 30uC for 1 hour. Samples are separated by SDS-
PAGE and analyzed by autoradiography.
doi:10.1371/journal.pone.0001375.g001
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Based on growth assays on glucose, the P1 mutant would be
expected to exhibit a higher basal kinase activity than the wild type
Pbs2. To test this hypothesis, we immunopurified wild type and
mutant forms of Pbs2 from yeast that were exposed to normal and
hyperosmotic conditions and analyzed them in an in vitro kinase
assay. As seen in Figure 5A, the P1 mutant protein, exhibits high
basal kinase activity in the absence of stimulus when compared to
wild-type Pbs2. As the tyrosine residue that is mutated in P1
(Y423) is conserved in all MKKs, we tested whether the same
mutation in mammalian MKK1 (Y130) would alter its basal
activity. Mutation of the conserved tyrosine to a histidine in the
mammalian MKK1 also resulted in high basal activity (Figure 5B).
As expected, MKK1 kinase activity is diminished in the presence
of YopJ, because the endogenous kinases are inhibited leaving only
the mutant kinases active (Figure 5B). These results support our
previous findings that YopJ inhibits the activation of MKKs and
that acetylation by YopJ cannot inhibit kinases that are
constitutively active (Figure 1) In addition, the P1 mutant might
reveal a novel mechanism to activate a kinase.
P4 and P5 mutants reveal the binding site for YopJ
The P4 mutation is located in Subdomain X on the small G a-
helix at the base of the carboxyl terminal lobe of the kinase
domain (Figure 2D). The mutation of a conserved isoleucine to a
phenylalanine disrupted the binding of YopJ to the mutant kinase
(Figure 3A). The P4 mutation is located on the side of the a-helix
that is exposed to solvent and we reasoned that this region might
be the binding site on the kinase domain for YopJ (Figure 6D). To
further investigate this possibility, we made a series of alanine
mutations (P15, P16, P17, and P20) in the conserved residues
along the G a-helix (Figure 6D). All of these mutants produced
functional kinases and were able to rescue the growth defect of
pbs2D strain on hyper-osmotic media (Figure S1B). Mutants P15
and P16, but not mutants P17 and P20, were able to interact with
YopJ, demonstrated by yeast two-hybrid analysis (Figure 6A). We
Figure 2. Pbs2 mutants that suppress YopJ inhibition thus survive on sorbitol plate. (A) Dilutions of yeast BY4741-pbs2D strain co-transformed
with YopJ and Pbs2 wild type or mutants are plated on synthetic media containing 2% raffinose, 1% galactose and 1 M sorbitol and incubated at
30uC. (B) Dilutions of yeast BY4741-pbs2D strain cotransformed with YopJ and Pbs2 wild type or mutants are plated on synthetic media containing
glucose and incubated at 30uC. (C) Sequence alignment shows all screened mutants are conserved in MKKs from yeast to human. (D) Structural
mapping of the screened mutants on a canonical MKK structure: P1 on beta strand 4; P4 on the G a-helix; P5 at the end of the G a-helix.
doi:10.1371/journal.pone.0001375.g002
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mutants was a substrate for YopJ in an acetyltransferase assay.
Only the mutants that bound to YopJ, P15 and P16, were
acetylated by YopJ (Figure 6B). The P17 and P20 mutants on the
G a-helix of the kinase domain did not bind to YopJ and were not
acetylated (Figure 6B). In contrast to P15 and P16 mutants, the P4,
P17 and P20 mutants are located on the same side of the G a-helix
that faces the APE-loop (see below).
Further analysis of the YopJ binding site revealed that the face
of the G a-helix that binds YopJ opposes the APE loop in the
kinase domain (Figure 6D). All MKKs, from yeast to human and
IKKb have either an isoleucine or a leucine residue facing the
binding site on the G a-helix. However, unlike the aforementioned
kinases that bind to YopJ, IKKa, which does not bind YopJ based
on in vitro pull down assays, has a phenylalanine at this position
[16]. Therefore, we tested whether a Pbs2 mutant containing
Ile531Phe (labeled P10) is an active kinase, binds to YopJ and is
acetylated by YopJ. We found that the P10 mutant was an active
kinase because it was able to rescue the hyper-osmotic sensitive
phenotype of pbs2D strain (Figure S1B) but P10 is unable to bind
to or be acetylated by YopJ (Figure 6A and 6B).
The last mutation identified from this genetic screen, P5, is
located at the end of the G a-helix and contains a leucine instead
of a proline. Although YopJ can bind to P5, we observed that YopJ
inefficiently acetylated P5 when compared to the wild type Pbs2
kinase domain (Figure 4 and 6B).
Further analysis of this binding site reveals that the YopJ
binding site is conserved in other MKKs. Two-hybrid analysis
with similar mutants in MKK (M4, M5, M15, M16, M17, and
M20) demonstrates that YopJ cannot bind to the predicted
interface of the helix if the corresponding residues are mutated or
a phenylalanine is present on the APE loop (Figure 6C).
DISCUSSION
MAPK pathways are conserved from yeast to man and each of the
corresponding kinases in the cascade are activated by a similar
mechanism. Yersinia strains express an effector protein, YopJ, that
inhibits the activation of the second kinase, MKK, in these signaling
pathways by acetylating residues that are normally phosphorylated
by the upstream kinase. From our genetic screen, we discovered that
a mutation in an evolutionarily conserved tyrosine residue is
sufficient to increase the basal activity of MKKs. We found that
the Ga-helixisthe binding siteonMKKsforYopJ. IfYopJisunable
to interact with this site, it cannot acetylate its substrate, MKK.
Figure 3. Interaction between YopJ and Pbs2 or MKK1 mutants. (A)
Yeast two-hybrid assay of the interaction between YopJ or YopJ(C172A)
mutant and Pbs2 wild type or Pbs2 mutants from the screening. (B)
Yeast two-hybrid assay of the interaction between YopJ or YopJ(C172A)
mutant and corresponding MKK1 mutants.
doi:10.1371/journal.pone.0001375.g003
Figure 4. Acetylation by YopJ of Pbs2 mutants is impaired. Recombinant YopJ or YopJ(C172A) is incubated with purified Pbs2 kinase domain or its
mutants in the presence and absence of
14C-labeled acetyl-CoA for 1 hour at 30uC. Samples are separated by SDS-PAGE and analyzed by
autoradiography.
doi:10.1371/journal.pone.0001375.g004
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tyrosine residue in MKK is linked to Cardio-facial-
cutaneous Syndrome
In the set of the evolutionarily conserved mutations, we isolated
the P1 mutant, in which a conserved tyrosine residue is mutated to
a histidine residue. The resulting suppressor mutant displays
increased basal activity in the absence of stimulus as observed in
both in vitro kinase assays and growth assays. We observe that
mutation of mammalian MKK at this position also results in a
kinase with high basal activity. We propose that mutation of the
conserved tyrosine residue results in an activated kinase by a
mechanism that is independent of phosphorylation. Therefore,
although the P1 suppressor mutant can still bind to YopJ and be
efficiently acetylated by YopJ, it bypasses the YopJ block and
activates the HOG MAPK pathway.
Recently, Rodriguez-Viciana and colleagues reported on the
genetics of activating mutations in the mammalian MAPK
pathway that cause Cardio-facial-cutaneous syndrome (CFC)
[17] (Online Mendelian Inheritance in Man (OMIM 115150)), a
disorder associated with cardiac defects, craniofacial features,
epidermal defects in hair and skin, and delay in development.
One of the activating mutations is found in MKK1 at the
conserved tyrosine (Y130) that aligns with the tyrosine residue
mutated in P1 (Y423H). Therefore, in two completely different
genetic surveys, using two distantly related species, an activating
mutation in the same conserved tyrosine residue was isolated.
Future structural studies comparing the wild-type inactive kinase
with the active mutant kinase, may reveal evolutionarily conserved
structural transition states important for the activation of this family
of kinases.
YopJ-binding site is on the G a-helix on MKKs
Using the Pbs2 suppressor screen we discovered that the G a-helix
is the binding site on MKKs for YopJ. Mutations along the side of
the G a-helix that is opposite of the APE loop disrupt the
interaction between YopJ and Pbs2p. Analogous mutations in the
G a-helix of mammalian MKK1 also disrupt binding of YopJ,
supporting the proposal that YopJ uses this region of the kinase as
a binding site on all members of the MKK family. Based on the
identification of the binding site for YopJ on MKKs, we have
learned at least three characteristics about the mechanism of YopJ
inhibition of the family of MKKs. The first and most obvious is
that YopJ must bind to its substrate to acetylate and inhibit it.
Second, we gained insight into why YopJ can inhibit some
kinases but not others [4]. During the early studies on the
mechanism of YopJ inhibition of signaling pathways, it was
observed that YopJ could bind all the mammalian MKKs and
IKKb (but not IKKa) and these kinases were known to play
integral roles in the induction of cytokine signaling and the innate
immune response. Based on our findings herein, we observe that
IKKa, but not IKKb or members of the MKK family, has a bulky
phenylalanine residue instead of an isoleucine or leucine residue
on its APE loop, which might block YopJ’s access to the binding
site on this kinase (Figure 6D). Mutation of Pbs2 at this site to a
phenylalanine creates a functional and inducible kinase. However,
the Pbs2(I531F) mutant acts as a YopJ suppressor, because it no
longer binds and, therefore, is not acetylated by YopJ. It is
reasonable to propose, from a mechanistic viewpoint, that the
reason YopJ cannot bind to IKKa is because the binding site on the
kinase is blocked. In contrast to these observations, Mittal and
colleagues observed YopJ-mediated acetylation of IKKa and IKKb
in transient transfection studies [9]. Both IKKa and IKKb are
Figure 5. P1 mutant exhibits a higher basal kinase activity. (A) Pbs2 wild type or P1 mutants expressed in yeast pbs2D strain with or without
sorbitol stimulation are purified and incubated with MBP and
32P-c-ATP at 30uC for 30 minutes. The samples are separated by SDS-PAGE, transferred
to PVDF membrane and then analyzed by autoradiography. The same membrane is probed with an anti-HA antibody. (B) HEK293 cells are transfected
with either Flag-tagged YopJ or YopJ(C172A), HA-tagged ERK and HA-tagged MKK1 wild type or M1 mutant. Cells are lysed and immunoprecipitated
using an anti-HA antibody and Protein G beads. Beads are separated using SDS-PAGE and probed with either anti-HA or anti-phospho ERK antibodies.
doi:10.1371/journal.pone.0001375.g005
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interact with this complex via IKKb and possibly acetylating both
kinases. Support of this hypothesis comes from the observation that
Pbs2(I531F)is a recessive mutant.Co-expression of Pbs2(I531F) with
wild type Pbs2 results in a yeast strain that is inhibited for growth on
high osmotic media (data not shown). In a manner similar to the
IKKa/IKKb heterodimer, the Pbs2/Pbs2I531F heterodimer may
be susceptible to YopJ inhibition.
Finally, the third characteristic involves the orientation of the
binding site on the kinase. P5contains a mutation ina proline residue
at the end of G a-helix and the proline is speculated to be a helix
breaker. We hypothesize that the P5 suppressor mutant, Pbs2(P584L)
contains a G a-helix that is extended by one amino acid and forms a
structure that is not optimal for YopJ inhibition because it alters
orientation of the YopJ binding site in Pbs2 and, as a result, we
observe the P5 suppressor mutant is inefficiently acetylated by YopJ.
Figure 6. The binding site on MKKs for YopJ. (A) Yeast two-hybrid assay of the interaction between YopJ or the YopJ(C172A) mutant and wild type
Pbs2 or mutants of Pbs2 in or around G a-helix. (B) Recombinant YopJ is incubated with purified Pbs2 kinase domain or mutants in or around the G a-
helix in the presence of
14C-labeled acetyl-CoA for 1 hour at 30uC. Samples are separated by SDS-PAGE and analyzed by autoradiography. Substrate
loading was controlled by protein staining. (C) Yeast two-hybrid assay of the interaction between YopJ or YopJ (C172A) mutant and corresponding
MKK1 mutants. (D) Structural mapping of G a-helix and APE domain, showing the mutants tested above.
doi:10.1371/journal.pone.0001375.g006
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Herein we have analyzed the inhibition of MAPK signaling by
Yersinia YopJ using yeast genetics. YopJ inhibits the MKK in the
HOG MAPK pathway by acetylation, thereby preventing its
activation by phosphorylation (Figure 1A). We have identified
suppressor mutants in the yeast Pbs2 that prevent YopJ from
inhibiting the MAPK pathways. The first mutant, P1, suppresses
YopJ inhibition by bypassing the requirement of phosphorylation
for activation. The second, P4, alters the binding site on MKKs so
that YopJ is unable to bind and modify the kinase. The third, P5, is
predicted to alter the orientation of the binding site for YopJ such
that it no longer efficiently modifies its substrate. Retrospectively,
it was fortunate that the pbs2 deletion strain is viable, because all
of the G a-helix mutants would not have been discovered in a
screen using the wild type yeast strain. Our findings have led to a
further understanding on how YopJ interacts with and modifies its
substrates. As Type III effectors are predicted to mimic or usurp a
eukaryotic catalytic activity, we believe the YopJ-binding site we
identified on the conserved G-helix will be an important binding
platform for eukaryotic signaling molecules that interact with this
family of kinases.
MATERIALS AND METHODS
Yeast Strains and Plasmids
HA tagged Pbs2 and mutants were generated in the yeast
expression vector pRS416-GPD1 and transformed into a pbs2D
strain or its parental strain, BY4741 (Research Genetics), together
with YopJ or YopJ(C172A) mutant encoded by a galactose
inducing vector pRS413-Gal1, by the lithium acetate procedure
[19]. Recombinant proteins were cloned into pET28a (His tagged)
or pGEX (GST tagged) vectors. Mutants were generated using the
Quickchange site-directed mutagenesis kit (Stratagene).
Yeast Culture
Yeasts were cultured at 30uC on plates or in liquid media
containing 2% glucose or 2% raffinose and 1% galactose in the
presence or absence of 1 M sorbitol. Specific amino acids were
excluded from the media for selection purposes. Dilution plating
experiments were performed using 5 ml cells per spot, starting with
an OD600 of 0.1 and serially diluting 5 times each step.
Genetic Screening of Pbs2 Mutants
A Pbs2 random mutagenesis library (9610
4 mutants) was
generated with a Stratagene kit and cloned into the pRS416-
GPD1 vector. The library was transformed into yeast strain
BY4741 pbs2D strain together with pRS413-Gal1-YopJ and
selected for growth on plates with 2% raffinose, 1% galactose
and 1 M sorbitol. A total 80 positive clones were identified, 24 of
which had a single mutation within the Pbs2 kinase domain.
Recombinant Protein Purification
Constructs of recombinant proteins were transformed into E. coli
BL21-DE3 strain and proteins were expressed by growing cells in
26YT media and inducing at an OD600 of 0.6,0.8 with 0.4 mM
IPTG. Cells were lysed by a cell disruptor and N-terminal His
tagged proteins (Pbs2 kinase domain and mutants, YopJ) were
purified using standard Ni
++-NTA affinity chromatography
purification protocols (Qiagen), while N-terminal GST tagged
YopJ was purified as indicated before [10]. After concentration
and buffer exchange, purified proteins were stored frozen in the
presence of 10% glycerol.
In vitro Acetylation Assay
In vitro acetylation assays were performed as described [10].
Briefly, recombinant YopJ or YopJ(C172A) was incubated with
purified Pbs2 kinase domain or its mutants in the presence and
absence of
14C-labeled acetyl-CoA for 1 hour at 30uC. Samples
were separated by SDS-PAGE and analyzed by autoradiography.
Immunoprecipitation from Yeast Extract and Kinase
Assay
Yeasts pbs2D strains co-expressing Pbs2 and YopJ were cultured in
media containing 2% raffinose and 1% galactose, harvested,
stimulated with 0.7 M sorbitol for 2.5 minutes, and lysed with 1%
Triton X-100 in 25 mM Tris, pH 7.5 and 150 mM NaCl, supplied
with protease and phosphatase inhibitors.HA tagged Pbs2 was pulled
down with an anti-HA antibody (Covance) and Protein G Sepharose
beads (Roche, Germany), which were washed with the same buffer
with 500 mM NaCl to eliminate nonspecific binding. Kinase assays
were performed as previously described [20] using MBP as substrate.
Briefly, purified Pbs2 on HA beads were incubated with MBP in the
presence of
32P-c-ATP, DTT and cold ATP at 30uC for 30 minutes,
separated by SDS-PAGE, and then analyzed by autoradiography.
Mammalian MKK1 Phosphorylation Experiment
HEK293 cells plated at a density of 0.5610
6 cells/ml were
transfected with either flag-tagged YopJ or YopJ C/A, HA-tagged
ERK and various HA-tagged MKK1 mutants. Cells were lysed in
HNT buffer containing protease inhibitors (0.01 M Hepes, pH 7.4,
0.05 M NaCl,1% Triton X-100, 0.5 mMNa3VO4,0.5 mMEGTA,
0.02 M NaF, 0.02 M b-glycerophosphate, and 1 mM DTT) and the
HA-MKK was immunoprecipitated using an anti-HA antibody
(Covance) and Protein G Sepharose beads (Roche). Total cell lysates
and beads were separated using SDS-PAGE and probed with either
anti-HA (Covance) or anti-phospho ERK antibodies (Cell Signaling).
Yeast Two-Hybrid
YopJ wild type or C172A mutant cloned into the pLexAde vector
(as bait) and Pbs2 or human MkK1 mutants cloned into the
pVP16 vector (as prey) were transformed into yeast strain L40
using the same method mentioned above. Yeasts were grown on
tryptophan- and leucine- deficient plates while two-hybrid
interactions were tested using a colony-lift b-gal assay and
visualized on nitrocellulose membranes [21].
SUPPORTING INFORMATION
Figure S1
Found at: doi:10.1371/journal.pone.0001375.s001 (0.68 MB TIF)
Figure S2
Found at: doi:10.1371/journal.pone.0001375.s002 (0.44 MB TIF)
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